Cerapedics, a Westminster, Colo.-based orthobiologics company, completed an $11m in Series D financing.
The backers were not disclosed.
The company intends to use the funds to expand commercialization of i-FACTOR™ Peptide Enhanced Bone Graft, which was approved by the U.S. Food and Drug Administration (FDA) in November 2015 for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease.
Additionally, the proceeds will be used to further the development of Cerapedics’ synthetic small peptide (P-15) technology for fusion in the lumbar spine.
Led by Glen Kashuba, CEO, Cerapedics focuses on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is a biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process.